Innovations in Vision and Cancer Treatment: Ocumetics Lens and Sapu003 Trials Show Promise
Update: 2025-10-08
Description
Ocumetics Technology Corp. reports positive outcomes for patients receiving the Ocumetics Accommodating Intraocular Lens, while Oncotelic Therapeutics Inc. prepares for clinical trials of Sapu003 to enhance Everolimus bioavailability. Additionally, Ohio State University Wexner Medical Center researchers discover TexPSR stress pathway impacting immunotherapy efficacy, offering hope for improved cancer treatment outcomes.
Comments
In Channel